• Featured Product
  • KD/KO Validated

Alpha Galactosidase A Monoklonaler Antikörper

Alpha Galactosidase A Monoklonal Antikörper für WB, IHC, IF/ICC, Indirect ELISA

Wirt / Isotyp

Maus / IgG2a

Getestete Reaktivität

human

Anwendung

WB, IHC, IF/ICC, Indirect ELISA

Konjugation

Unkonjugiert

CloneNo.

2B2C5

Kat-Nr. : 66121-1-PBS

Synonyme

GLA, 2B2C5, Alpha-D-galactosidase A, Alpha-D-galactoside galactohydrolase, Alpha-galactosidase A



Geprüfte Anwendungen

Produktinformation

66121-1-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA Alpha Galactosidase A und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Maus / IgG2a
Klonalität Monoklonal
Typ Antikörper
Immunogen Alpha Galactosidase A fusion protein Ag7505
Vollständiger Name galactosidase, alpha
Berechnetes Molekulargewicht 49 kDa
Beobachtetes Molekulargewicht 49 kDa
GenBank-ZugangsnummerBC002689
Gene symbol GLA
Gene ID (NCBI) 2717
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

GLA, also named as Melibiase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.